aTYR PHARMA INC (ATYR) Return on equity 2019–2025
aTYR PHARMA INC (ATYR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-109.8%FY2025 · since FY2019: -76.6% → -109.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -109.8% | -18.4 pp |
| FY2024 | -91.4% | -35.9 pp |
| FY2023 | -55.6% | +7.9 pp |
| FY2022 | -63.4% | -32.5 pp |
| FY2021 | -30.9% | +20.4 pp |
| FY2020 | -51.3% | +25.3 pp |
| FY2019 | -76.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ATYR financial trends
ATYR RevenueATYR Net incomeATYR Net marginATYR Gross profitATYR Gross marginATYR Operating incomeATYR Operating marginATYR Operating cash flowATYR Free cash flowATYR Capital expendituresATYR Stock buybacksATYR Dividends paidATYR Total assetsATYR Total liabilitiesATYR Shareholders’ equityATYR overview →